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• Splanchnic venous thrombosis (SVT) is a known complication 
of pancreatitis.
• SVT is more common in acute pancreatitis (AP), occurring in 
about 22.6% of cases of AP compared to 12.4% of cases of 
acute recurrent pancreatitis (ARP) and chronic pancreatitis 
(CP)1.
• The incidence of SVT in pediatric ARP and CP is not known.
• A single center retrospective study reported an incidence of 
4.04% in children with CP2.
• The treatment of pancreatitis-induced SVT with anticoagulants 
is controversial.
• The use of direct oral anticoagulants (DOACs) in children is 
highly debated.
• Here, we report 2 children with ARP and CP who had 
pancreatitis-induced SVT and were successfully treated with 
DOACs without complications.
CASE 1
13-year-old female with obesity (BMI 99%tile) 
presents with 2nd episode of acute pancreatitis
• Started on IV fluids, opioids, and prophylactic enoxaparin
• Day 6: lack of clinical improvement
• CT shows nonocclusive splenic vein thrombosis
• Previous CT at OSH had no signs of thrombosis
• Changed to therapeutic enoxaparin until appropriate levels 
obtained
• Switched to oral rivaroxaban prior to discharge
• 3 months later, follow up imaging showed thrombosis resolution 
DISCUSSION
INTRODUCTION
Images: CT of splenic vein thrombosis in case 1 (arrow in A) and subsequent 
resolution (arrow in B). CT of extensive splenic vein thrombosis in case 2 
(arrow in C) and subsequent resolution (arrow in D).
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CASE 2
9-year-old female with obesity (BMI 99%tile) 
presents with 3rd episode of acute pancreatitis
• Started on IV fluids and opioids
• Day 3: lack of clinical improvement
• CT shows an occlusive splenic vein thrombosis extending 
into the main portal vein and SMV
• Started on therapeutic enoxaparin
• Displayed significant needle phobia in the hospital 
• Switched to oral rivaroxaban at discharge
• 5 months later, follow up imaging showed near complete 
resolution of thrombus
• Use of DOACs in our limited pediatric case series of 
pancreatitis-induced thromboses (PIT) led to recanalization 
without any adverse effects.
• DOAC use for adults with thromboses are as effective and safe 
as conventional injectable low-molecular-weight heparin 
(LMWH)3.
• Some adult studies report complete recanalization of 
thromboses in >80% of patients started on DOACs4.
• DOAC use in pediatric thromboses is currently under 
investigation, with phase III clinical trials showing they are at 
least as effective and safe as LMWH5.
• Needle phobia leads to poor compliance and should be 
considered when starting children on anticoagulants for 
thrombosis treatment6.
• Prospective studies for anticoagulant use (especially DOACs) in 
pediatric PIT are needed.
